ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.
Women’s Health and Urology
In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray) as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.
ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.
Central Nervous System (CNS)
In CNS, ReHealth is advancing programs to treat critical conditions such as Major Depressive Disorder (MDD), Migraine and Alzheimer’s disease. Key programs include rapastinel (MDD) Ubrogepant (Acute Migraine), M1, M4 and M1/M4 Agonists (Alzheimer’s disease) and an NR2Br Antagonist (OCD/Autism).